Cargando…

Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus

Adenovirus vector vaccines have been the mainstream research direction of CSF vaccines, due to the replication deficiency of adenovirus vectors, achieving double effects with the safety of inactivated vaccines and the efficacy of live vaccines. Therefore, the E0 and E2 genes were expressed by an ade...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Heng, Yin, Dehua, Qin, Huairui, Zhang, Ke, Li, Zhaoyang, Cui, Guangchao, Ma, Guangbin, Sun, Peng, Cao, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673476/
https://www.ncbi.nlm.nih.gov/pubmed/36406388
http://dx.doi.org/10.3389/fmicb.2022.1054651
_version_ 1784832949050408960
author Zhang, Heng
Yin, Dehua
Qin, Huairui
Zhang, Ke
Li, Zhaoyang
Cui, Guangchao
Ma, Guangbin
Sun, Peng
Cao, Zhi
author_facet Zhang, Heng
Yin, Dehua
Qin, Huairui
Zhang, Ke
Li, Zhaoyang
Cui, Guangchao
Ma, Guangbin
Sun, Peng
Cao, Zhi
author_sort Zhang, Heng
collection PubMed
description Adenovirus vector vaccines have been the mainstream research direction of CSF vaccines, due to the replication deficiency of adenovirus vectors, achieving double effects with the safety of inactivated vaccines and the efficacy of live vaccines. Therefore, the E0 and E2 genes were expressed by an adenovirus vector, a recombinant adenovirus E0-E2 (rAd-E0-E2) vaccine was constructed, and the minimum immunization dose and immune duration period were determined in this study. Forty healthy piglets were randomly divided into 8 groups (n = 5). Groups 1 ~ 5 were used to determine the minimum immunization dose, and 5 groups were inoculated with rAd-E0-E2 at different immune doses. Serum was collected at 7 d and 14 d after immunization to detect CSFV antibodies by ELISA, and piglets were challenged at 7 d post immunization. Groups 6 ~ 8 were immunized with 1 dose of rAd-E0-E2, the CSFV live attenuated vaccine C strain and saline to identify the immune duration period. Serum was collected at different time points after immunization, CSFV antibodies were detected by ELISA, and piglets were challenged at 8 months post immunization. Meanwhile, temperature, clinical symptoms and pathology were observed. The results of groups 1 ~ 5 showed that 1 piglet was protected after challenge, and 4 piglets exhibited high fever retention, typical CSFV symptoms and tissue lesions in the 1/50 dose group, whereas no clinical symptoms were observed in the 1/10 dose, 1/5 dose or 1 dose groups with 5/5 protection after challenge. The minimum dose was determined as 1/10 dose. The results of groups 6 ~ 8 showed that all piglets survived after challenge, but the antibody level of the rAd-E0-E2 strain was higher than that of the C strain at 8 months post immunization, and all piglets in the negative group developed the disease process after challenge. Overall, the minimum immunization dose of rAd-E0-E2 was 1/10 dose (3.16 × 10(6.0) IFU) and the minimum immune dose was determined to be 1 dose (3.16 × 10(7.0) IFU) to achieve the expected effects. The immune duration period of piglets immunized with 1 dose of rAd-E0-E2 was at least 8 months.
format Online
Article
Text
id pubmed-9673476
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96734762022-11-19 Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus Zhang, Heng Yin, Dehua Qin, Huairui Zhang, Ke Li, Zhaoyang Cui, Guangchao Ma, Guangbin Sun, Peng Cao, Zhi Front Microbiol Microbiology Adenovirus vector vaccines have been the mainstream research direction of CSF vaccines, due to the replication deficiency of adenovirus vectors, achieving double effects with the safety of inactivated vaccines and the efficacy of live vaccines. Therefore, the E0 and E2 genes were expressed by an adenovirus vector, a recombinant adenovirus E0-E2 (rAd-E0-E2) vaccine was constructed, and the minimum immunization dose and immune duration period were determined in this study. Forty healthy piglets were randomly divided into 8 groups (n = 5). Groups 1 ~ 5 were used to determine the minimum immunization dose, and 5 groups were inoculated with rAd-E0-E2 at different immune doses. Serum was collected at 7 d and 14 d after immunization to detect CSFV antibodies by ELISA, and piglets were challenged at 7 d post immunization. Groups 6 ~ 8 were immunized with 1 dose of rAd-E0-E2, the CSFV live attenuated vaccine C strain and saline to identify the immune duration period. Serum was collected at different time points after immunization, CSFV antibodies were detected by ELISA, and piglets were challenged at 8 months post immunization. Meanwhile, temperature, clinical symptoms and pathology were observed. The results of groups 1 ~ 5 showed that 1 piglet was protected after challenge, and 4 piglets exhibited high fever retention, typical CSFV symptoms and tissue lesions in the 1/50 dose group, whereas no clinical symptoms were observed in the 1/10 dose, 1/5 dose or 1 dose groups with 5/5 protection after challenge. The minimum dose was determined as 1/10 dose. The results of groups 6 ~ 8 showed that all piglets survived after challenge, but the antibody level of the rAd-E0-E2 strain was higher than that of the C strain at 8 months post immunization, and all piglets in the negative group developed the disease process after challenge. Overall, the minimum immunization dose of rAd-E0-E2 was 1/10 dose (3.16 × 10(6.0) IFU) and the minimum immune dose was determined to be 1 dose (3.16 × 10(7.0) IFU) to achieve the expected effects. The immune duration period of piglets immunized with 1 dose of rAd-E0-E2 was at least 8 months. Frontiers Media S.A. 2022-10-28 /pmc/articles/PMC9673476/ /pubmed/36406388 http://dx.doi.org/10.3389/fmicb.2022.1054651 Text en Copyright © 2022 Zhang, Yin, Qin, Zhang, Li, Cui, Ma, Sun and Cao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Zhang, Heng
Yin, Dehua
Qin, Huairui
Zhang, Ke
Li, Zhaoyang
Cui, Guangchao
Ma, Guangbin
Sun, Peng
Cao, Zhi
Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus
title Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus
title_full Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus
title_fullStr Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus
title_full_unstemmed Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus
title_short Immunogenicity of the recombinant adenovirus fusion-expressing E0-E2 gene of the classical swine fever virus
title_sort immunogenicity of the recombinant adenovirus fusion-expressing e0-e2 gene of the classical swine fever virus
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673476/
https://www.ncbi.nlm.nih.gov/pubmed/36406388
http://dx.doi.org/10.3389/fmicb.2022.1054651
work_keys_str_mv AT zhangheng immunogenicityoftherecombinantadenovirusfusionexpressinge0e2geneoftheclassicalswinefevervirus
AT yindehua immunogenicityoftherecombinantadenovirusfusionexpressinge0e2geneoftheclassicalswinefevervirus
AT qinhuairui immunogenicityoftherecombinantadenovirusfusionexpressinge0e2geneoftheclassicalswinefevervirus
AT zhangke immunogenicityoftherecombinantadenovirusfusionexpressinge0e2geneoftheclassicalswinefevervirus
AT lizhaoyang immunogenicityoftherecombinantadenovirusfusionexpressinge0e2geneoftheclassicalswinefevervirus
AT cuiguangchao immunogenicityoftherecombinantadenovirusfusionexpressinge0e2geneoftheclassicalswinefevervirus
AT maguangbin immunogenicityoftherecombinantadenovirusfusionexpressinge0e2geneoftheclassicalswinefevervirus
AT sunpeng immunogenicityoftherecombinantadenovirusfusionexpressinge0e2geneoftheclassicalswinefevervirus
AT caozhi immunogenicityoftherecombinantadenovirusfusionexpressinge0e2geneoftheclassicalswinefevervirus